Effectiveness of In-Hospital Cholecalciferol Use on Clinical Outcomes in Comorbid COVID-19 Patients: A Hypothesis-Generating Study
Nutrients 2021, 13(1), 219; https://doi.org/10.3390/nu13010219
For those with 3 or more major health problems
100% died if no vitamin D but only 40% died if had gotten vitamin D
Vitamin D was give to those who had the worse prognosis
200,000 IU on 2nd day in hospital + 200,000 IU on 3rd day in hospital
Note by VitaminDWiki: Better survival expected if
- Give it all on the first day in hospital - not wait for the 2nd and 3rd day
- and, far better, give vitamin D on the first day of having symptoms
- Use a gut-firendly form of vitamin D if symptoms are so bad that a person is in hospitsl
As of March 6 this page had: 34 trials, 5 trial results, 14 meta-analyses and reviews, 47 observations, 31 recommendations, 47 associations, 85 speculations, 42 videos see related: Governments, HealthProblems, Hospitals, Dark Skins, 26 risk factors are ALL associated with low Vit D, Recent Virus pages Fight COVID-19 with 50K Vit D weekly
- All COVID-19 patients had low vitamin D, the lowest were more likely to die – Feb 18, 2021
- 2.7 fewer COVID-19 hospital deaths in those having more than 30 ng of vitamin D – Mayo Jan 9, 2021
- Worse COVID-19 patients got 400,000 IU of vitamin D, deaths cut in half – Jan 14, 2021
- Iranians with COVID-19 were 2.3 X more likely to die if low vitamin D – Jan 2021
- Poor COVID-19 prognosis was 6 X more likely if low vitamin D – Jan 21, 2021
- 30 x fewer COVID-19 deaths in those getting 400,000 IU of Vitamin D - Jan 2021
- 2.8 X fewer COVID-19 nursing home deaths if add 10,000 IU Vitamin D daily for a week (small observation)- Jan 2021
- Italian nursing home COVID-19 – 4X less likely to die if taking Vitamin D– Dec 22, 2020
- Those getting intermittent vitamin D were 7 X less likely to die of COVID-19 - Dec 11, 2020
- COVID-19 male mortality increased 3.9 X if low vitamin D – observation Nov 25, 2020
- Hospital COVID-19 observation: 7X more likely to live if more than 20 ng of vitamin D– Nov 19, 2020
- COVID-19 lung death 4X more likely in Iran if less than 25 ng of vitamin D – Oct 30, 2020
- 9X COVID-19 survival in nursing home if had 80,000 IU dose of vitamin D in previous month – Oct 2020
- 14.7 X more likely to die of COVID-19 if less than 12 ng of Vitamin D (185 Germans) – Sept 10, 2020
- COVID ARDS deaths 2X more likely if less than 10 ng of Vitamin D – Aug 8, 2020
- COVID-19 mortality rate highest North of 35 degrees latitude (Vitamin D) – April 20, 2020
Note: >70% of the trials using Vitamin D to fight COVID-19 are using
at least 100,000 IU during the first week
Little information is available on the beneficial effects of cholecalciferol treatment in comorbid patients hospitalized for COVID-19. The aim of this study was to retrospectively examine the clinical outcome of patients receiving in-hospital high-dose bolus cholecalciferol. Patients with a positive diagnosis of SARS-CoV-2 and overt COVID-19, hospitalized from 15 March to 20 April 2020, were considered. Based on clinical characteristics, they were supplemented (or not) with 400,000 IU bolus oral cholecalciferol (200,000 IU administered in two consecutive days) and the composite outcome (transfer to intensive care unit; ICU and/or death) was recorded.
Ninety-one patients (aged 74 ± 13 years) with COVID-19 were included in this retrospective study. Fifty (54.9%) patients presented with two or more comorbid diseases.
Based on the decision of the referring physician, 36 (39.6%) patients were treated with vitamin D.
Receiver operating characteristic curve analysis revealed a significant predictive power of the four variables:
- (a) low (<50 nmol/L) 25(OH) vitamin D levels,
- (b) current cigarette smoking,
- (c) elevated D-dimer levels
- (d) and the presence of comorbid diseases,
to explain the decision to administer vitamin D (area under the curve = 0.77, 95% CI: 0.67–0.87, p < 0.0001).
Over the follow-up period (14 ± 10 days), 27 (29.7%) patients were transferred to the ICU and 22 (24.2%) died (16 prior to ICU and six in ICU).
Overall, 43 (47.3%) patients experienced the combined endpoint of transfer to ICU and/or death. Logistic regression analyses revealed that the comorbidity burden significantly modified the effect of vitamin D treatment on the study outcome, both in crude (p = 0.033) and propensity score-adjusted analyses (p = 0.039), so the positive effect of high-dose cholecalciferol on the combined endpoint was significantly amplified with increasing comorbidity burden. This hypothesis-generating study warrants the formal evaluation (i.e., clinical trial) of the potential benefit that cholecalciferol can offer in these comorbid COVID-19 patients.
- - - - -
Clipped from PDF
"Overall, 43 (47.3%) patients experienced the combined endpoint of transfer to ICU or death. In a crude analysis, initially including comorbidity burden as a potential confounder, vitamin D treatment was observed to be associated with a 43% and 55% reduction, respectively, in the OR of the combined endpoint, but these effects did not attain statistical significance (Table 3)"
Summary: 55% less likely to die, but too few of people to be statistically significant
There have actually been
|321 visitors, last modified 07 Feb, 2021,